| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f17e1f3189d876840dec034fe61837f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba3f70d4bcad1958ae8868ddab079b8f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate |
2017-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3710fbc096e1923ccee86c58bb241fc0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d69a8a54ee3ee583f99a7ac79c62fc29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ce9dc1127d426fb1e2feb2cf8fce856 |
| publicationDate |
2019-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019290691-A1 |
| titleOfInvention |
Fusion protein for use in the treatment of hvg disease |
| abstract |
The invention provides a fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 or SLA-01*0401 in a recipient patient who is negative for HLA-A*02 or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02 or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02 or SLA-01*0401. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021230251-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020368279-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021244759-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11660315-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022165419-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021079149-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022115343-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11602543-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11602544-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019248869-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11730764-B2 |
| priorityDate |
2016-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |